SLC5A5 and ovarian cancer: Notably, also an innovative application scheme is included in the protocol of another MV-NIS clinical trial on therapy-resistant ovarian cancer (NCT02068794): intraperitoneal application on the first course with MV-NIS is followed by subsequent courses every 4 weeks for up to six courses with MV-NIS-infected mesenchymal stem cells.